Digistain Technology Features & Advantages
Digistain reports the Digistain Prognostic Score, recurrence-risk information designed as a lower-cost alternative to RNA-based genomic testing.
VALIDATED – evaluated in a retrospective validation study of 801 patients, designed for integration within histopathology workflows to support MDT risk stratification
FAST – designed to return results within 1-2 days of specimen receipt at our UK laboratory (courier transit is additional)
COST-EFFECTIVE – unlike traditional tumour profiling technologies, Digistain is reagent free, with a streamlined workflow
ACCESSIBLE – designed as a lower-cost process, with results returned within 1-2 days of specimen receipt at our UK laboratory
CLEAR – provides an easy-to-read pathology report with a low or high-risk classification on the likelihood of breast cancer recurrence in the next 10 years
RNA-FREE – Digistain uses spectroscopic features of FFPE tissue sections and does not require RNA extraction
APPLICABLE – has broad ethnic applicability and is suitable for people all around the world
COMPATIBLE – works with current hospital diagnostic workflows, supported by robust quality management systems, and applied to already available tumour samples prepared using standard processing methods
ENVIRONMENTAL – Avoids the high carbon footprint associated with genomic tests that require large volumes of chemical reagents — and where centralised processing can introduce logistical dependencies, including international air shipment of samples
No change to workflow using Digistain®
Digistain Prognostic Score – Breast is an in vitro diagnostic test for professional use. The result is an estimate of the risk of recurrence and is probabilistic. It is used with, and does not replace, established clinico-pathological factors and clinical judgement. Treatment decisions remain with the treating clinician.